Latest News About Chris Gibson

I don’t have live tool access right now to fetch the very latest updates, but here’s what’s publicly known about Chris Gibson recently:

• Chris Gibson, the former CEO of Recursion Pharmaceuticals, stepped down as CEO at the end of 2025 and was succeeded by Najat Khan. He later indicated he would not seek re-election to Recursion’s board, continuing as an advisor to the company through mid-2026. This marks a transition phase for Gibson and Recursion.[1][2]

• In early 2026, reports noted Gibson’s ongoing involvement with Recursion in an advisory capacity while shifting focus away from board duties, aligning with broader leadership changes at the company as it refines its pipeline and strategy.[2]

• There are various unrelated or tangential items about individuals named “Chris Gibson” in other domains (sports, skincare, academia, etc.), but they are not connected to the Recursion-era tech/biotech executive you likely mean. When searching for “Chris Gibson,” it’s important to distinguish the Recursion biotech executive from others with the same name.[3][5][1]

If you’d like, I can try to pull the most current sources again or narrow the search to Recursion-related news (e.g., earnings calls, board changes, or leadership profiles) for a precise, up-to-date snapshot. Additionally, tell me if you’re interested in a quick timeline or a side-by-side summary of his roles and impact at Recursion.

Citations:

• Recursion board and leadership changes, including not seeking re-election and transitioning to advisor.[2]
• Andrew Dunn’s post highlighting Gibson stepping down as CEO and the broader context at Recursion.[1]
• General notes distinguishing Chris Gibson in other fields (to avoid confusion).[5][3]